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osoWe report the results of the International Infection Control Consortium (INICC) surveillance study from January 2003 through
December 2008 in 173 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study, using Centers
for Disease Control and Prevention (CDC) US National Healthcare Safety Network (NHSN; formerly the National Nosocomial Infec-
tion Surveillance system [NNIS]) definitions for device-associated health care-associated infection, we collected prospective data
from 155,358 patients hospitalized in the consortium’s hospital ICUs for an aggregate of 923,624 days. Although device utilization
in the developing countries’ ICUs was remarkably similar to that reported from US ICUs in the CDC’s NHSN, rates of device-asso-
ciated nosocomial infection were markedly higher in the ICUs of the INICC hospitals: the pooled rate of central venous catheter
(CVC)-associated bloodstream infections (BSI) in the INICC ICUs, 7.6 per 1000 CVC-days, is nearly 3-fold higher than the 2.0 per
1000 CVC-days reported from comparable US ICUs, and the overall rate of ventilator-associated pneumonia (VAP) was also far
higher, 13.6 versus 3.3 per 1000 ventilator-days, respectively, as was the rate of catheter-associated urinary tract infection (CAUTI),
6.3 versus 3.3 per 1000 catheter-days, respectively. Most strikingly, the frequencies of resistance of Staphylococcus aureus isolates
to methicillin (MRSA) (84.1% vs 56.8%, respectively), Klebsiella pneumoniae to ceftazidime or ceftriaxone (76.1% vs 27.1%, respec-
tively), Acinetobacter baumannii to imipenem (46.3% vs 29.2%, respectively), and Pseudomonas aeruginosa to piperacillin (78.0%
vs 20.2%, respectively) were also far higher in the consortium’s ICUs, and the crude unadjusted excess mortalities of device-related
infections ranged from 23.6% (CVC-associated bloodstream infections) to 29.3% (VAP).
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Consortium; device-associated infection; antibiotic resistance; ventilator-associated pneumonia; catheter-associated urinary tract
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March 2010This report is a summary of data on device-associ-
ated infections (DAI) within intensive care units (ICUs)
collected by hospitals participating in the International
Nosocomial Infection Control Consortium (INICC)1-13
between January 2003 and December 2008.
The INICC is an international nonprofit, open, multi-
center, collaborative health care-associated infection
control program with a surveillance system based on
that of the US National Healthcare Safety Network
(NHSN; formerly the National Nosocomial Infection
Surveillance system [NNIS]).3 Founded in Argentina in
1998, the INICC is the first multinational research net-
work established to control and reduce DAI through the
analysis of data collected on a voluntary basis by a pool
of hospitals worldwide. The INICC has the following
goals: Create a dynamic global network of hospitals
in the developing world that conducts surveillance of
health care-associated infections (HAIs) using stan-
dardized definitions and established methodologies,
promote implementation of evidence-based infection
control practices, and carry out applied infection con-
trol research; provide training and surveillance tools
to individual hospitals that can allow them to conduct
outcome and process surveillance of HAIs, measure
their consequences, and assess the impact of infection
control practices; to improve the safety and quality of
health care worldwide through implementation of sys-
tematized programs to reduce rates of HAI, associated
mortality, excess lengths of stay, excess costs, and bac-
terial resistance.
METHODS
The INICCat this timehas focusedonsurveillance and
prevention of DAI in adult and pediatric ICUs and high-
risknurseries.3Thedataare collectedusing standardized
CDC NNIS/NHSN protocols and definitions.14-16
The INICC has both outcome surveillance and pro-
cess surveillance components. The modules of the
components may be used singly or simultaneously,
but, once selected, they must be used for a minimum
of 1 calendar month.
All DAIs of the Outcome Surveillance Component,
are categorized using standard CDC NNIS definitions
that include laboratory and clinical criteria. Both labo-
ratory-confirmed bloodstream infections (BSIs) and
clinical sepsis without microbiologic confirmation of
BSI are recorded and reported.15
Within the Outcome Surveillance Component, data
are classified into specific module protocols addressing
the following: DAI rates: excess length of stay, evalua-
tion of HAI costs, crude excess mortality, microbiologic
profile, bacterial resistance, and antimicrobial-use data.
In addition, INICC methodology includes a process for
adjudication of and validation of reported HAIs.3Infection control professionals (ICPs) collect data on
central line-associated primary bloodstream infections
(CLABs), catheter-associated urinary tract infections
(CAUTIs), and ventilator-associated pneumonias (VAPs)
occurring in patients hospitalized in a specific patient
care location, in nearly all hospitals. ICUs are stratified
according to the patient population: adult, pediatric,
or neonatal units (NICUs).
All NICUs are level III or level II/III units, and ICPs
collect data on CLABs and umbilical catheter-associ-
ated primary BSIs or VAPs for each of 5 birth-weight
categories (,750 g, 750-1000 g, 1001-1500 g, 1501-
2500 g, .2500 g). Corresponding denominator data,
patient-days, and specific device-days are also
collected.
Small proportion of hospitals, with previous long-
lasting experience conducting surveillance of DAIs,
sent aggregated data to the INICC. Original and aggre-
gated data were collected to calculate DAI rates. Only
original data were collected to calculate mortality and
lengh of stay.
The Process Surveillance Component includes the
following modules: hand hygiene compliance monitor-
ing in ICUs; central and peripheral vascular catheter
care compliance monitoring; urinary catheter care
compliance monitoring; monitoring of compliance
with measures to prevent VAP; and performance feed-
back. Data from the Process Surveillance Module on
hand hygiene compliance are included in this report.
The identity of all INICC hospitals, cities, and countries
is confidential, in accordance with the INICC charter.
RESULTS
Characteristics of 173 ICUs from 25 countries in
Latin America, Asia, Africa, and Europe currently par-
ticipating in the INICC that contributed data for this re-
port are shown in Table 1. The participation of
hospitals on the INICC Program is as follows: mean
length of participation 6 SD, 22.9 6 21.6 months,
range 1 to 72 months. One hundred thirty-nine out
of 173 (81%) of ICUs collected and sent original data
to INICC headquarters, and 34 out of 173 (19%) of
ICUs collected and sent aggregated data to INICC head-
quarters. Original and aggregated data were used to
calculate DAI rates. Only original data were used to
calculate mortality and lengh of stay.
For the Outcome Surveillance Component, DAI
rates, device utilization (DU) ratios, crude excess mor-
tality by specific type of DAI, antimicrobial utilization,
and bacterial resistance for January 2003 through
December 2008 are summarized (Tables 2-17).
Tables 2-7 show DAI rates and DU ratios by infection
type (CLAB, CAUTI, VAP) in adult and pediatric ICUs. The
data were not stratified by type or size of hospital.
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Rosenthal et al. 97Device-days consisted of the total number of central line-
days,urinarycatheter-days, or ventilator-days.TheDUra-
tio constitutes an extrinsic risk factor for HAI.17 DU also
comprises a marker for severity of illness of patients,
vis-a-vis, patients’ susceptibility to HAI.
Tables 8-11 show DAI rates and DU ratios from the
High Risk Nursery Component of the INICC system
for CLABs and VAPs. For NICUs, device-days consist of
the total number of central line-days, umbilical cathe-
ter days, and ventilator-days. The data for neonatal
ICUs were stratified by weight.
Tables 12 and 13 provide data on crude ICU mortal-
ity in patients hospitalized in each type of unit during
the surveillance period, with and without DAI, and
crude excess mortality of adult and pediatric patients
with CLAB, CAUTI, and VAP and infants in NICUs with
CLAB or VAP.
Tables 14 and 15 provide data on crude length of
stay of patients hospitalized in each type of unit during
the surveillance period with and without DAI and crude
excess length of stay of adult and pediatric patients
with CLAB, CAUTI, and VAP and infants in NICUs with
CLAB or VAP.
Table 16 provides data on bacterial resistance of path-
ogens isolated from patients with DAI in adult and pedi-
atric ICUs and NICUs. Table 17 provides data on hand
hygiene compliance in each type of unit. Tables 18 and
19 compare overall rates of CLAB, CAUTI, and VAP (Table
18)18 and rates of antimicrobial resistance (Table 19)19 in
the INICC and CDC NHSN ICUs.
DISCUSSION
The effectiveness of implementing an integrated in-
fection control program focused on HAI surveillance
was demonstrated approximately 30 years ago, as
shown in the many studies conducted in the United
States, whose results reported not only that the inci-
dence of HAI can be reduced by as much as 30% but
that a related reduction in health care costs was also
feasible.20 For more than 30 years, the CDC’s NNIS/
NHSN network has provided benchmarking US ICU
data on DAIs and antibiotic resistance, which have
proven invaluable for researchers,17-19,21-24 and served
as an inspiration to the INICC program. Initially, INICC’s
surveillance concentrated on DAI surveillance in the
ICU, a health care setting with the highest HAI rates
and in which patients’ safety is most seriously threat-
ened because of their critical condition and exposure
to invasive devices.3
The rate of device use in INICC ICUs is analogous or
even lower to the one reported of US ICUs by the NNIS/
NHSN system18,24; however, DAI rates identified in IN-
ICC ICUs are exceedingly higher than the published
US rates (Table 18).18 Likewise, the antimicrobial
Table 2. Pooled means and 95% CI of the distribution of central line-associated BSI rates, per 1000 central line-days by type
of adult and pediatric ICU
Type of ICU
No. of
ICUs
No. of
patients
No. of CLAB
(LCBI)*
No. of CLAB
(CSEP)y
No. of CLAB
(LCBI 1 CSEP)
Central
line-days
Pooled mean
CLAB rate 95% CI
Coronary 9 8845 52 184 236 27,768 8.5 7.5-9.7
Surgical-cardiothoracic 4 1683 18 7 25 6998 3.6 2.3-5.3
Medical 12 11,410 170 10 180 20,034 9.0 7.7-10.4
Medical-surgical 83 85,989 2362 332 2694 362,882 7.4 7.2-7.7
Neurosurgical 5 2996 93 2 95 5367 17.7 14.3-21.6
Pediatric 22 23,047 383 74 457 58,842 7.8 7.1-8.51
Surgical 13 7925 207 22 229 27,313 8.4 7.3-9.54
Trauma 3 2237 28 0 28 8975 3.1 2.07-4.51
Burn 1 191 0 0 0 9 0.0 -
Overall 152 144,323 3313 698 3944 518,188 7.6 7.4-7.9
BSI, bloodstream infection; CLAB, central line-associated BSI.
*Laboratory-confirmed BSI.
yClinical sepsis, without laboratory confirmation.
Table 3. Pooled means and 95% CI of central line utilization ratios by type of adult and pediatric ICU
Type of ICU No. of ICUs Central line-days Patient-days Pooled mean DUR 95% CI
Coronary 9 27,768 41,289 0.67 0.67-0.68
Surgical-cardiothoracic 4 6998 7495 0.93 0.93-0.94
Medical 12 20,034 53,022 0.38 0.37-0.38
Medical-surgical 83 362,882 495,115 0.73 0.73-0.73
Neurosurgical 5 5367 17,073 0.31 0.31-0.32
Pediatric 22 58,842 129,657 0.45 0.45-0.46
Surgical 13 27,313 42,275 0.65 0.64-0.65
Trauma 3 8975 14,726 0.61 0.60-0.62
Burn 1 9 2156 0.004 0.002-0.01
Overall 152 518,188 802,808 0.65 0.64-0.65
DUR, Device use ratio.
Table 4. Pooled means and 95% CI of the distribution of catheter-associated UTI rates, per 1000 urinary catheter-days
by type of adult or pediatric ICU
Type of ICU No. of ICUs No. of Patients Urinary catheter-days No. of CAUTIs Pooled mean CAUTI rate 95% CI
Coronary 9 8845 21,595 94 4.4 3.5-5.3
Surgical-cardiothoracic 4 1683 6984 3 0.4 0.1-1.3
Medical 12 11,410 33,318 284 8.5 7.6-9.6
Medical-surgical 83 85,989 403,545 2479 6.1 5.9-6.4
Neurosurgical 5 2996 14,716 204 13.9 12.0-15.9
Pediatric 22 23,047 21,921 96 4.4 3.6-5.4
Surgical 13 7925 29,268 146 5.0 4.2-5.9
Trauma 3 2237 9861 82 8.3 6.6-10.3
Burn 1 191 402 2 5.0 0.6-17.9
Overall 152 144,323 541,610 3390 6.3 6.0-6.5
CAUTI, catheter-associated urinary tract infection.
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March 2010resistance rates found in INICC ICUs for Staphylococcus
aureus isolates as resistant tomethicillin (MRSA), enter-
obacteria resistant to ceftazidime (extended-spectrum
b-lactamase producers), and Pseudomonas aeruginosa
as resistant to fluoroquinolones were far higher than
NHSN ICUs’ rates (Table 19).19 Nonetheless, the rates
found in the INICC ICUs for enterococcal isolates asresistant to vancomycin is much lower than NHSN
ICUs’ rates.19
These higher DAI ratesmay reflect the typical ICU sit-
uation in limited-resources countries as a whole,25,26
and several reasons have been exposed to explain this
fact.27 Among the primary plausible causes, it can be
mentioned that, in themajority of the limited-resources
Table 7. Pooled means and 95% CI of ventilator utilization ratios by type of adult or pediatric ICU
Type of ICU No. of units Patient-days Ventilator-days Pooled mean DUR 95% CI
Coronary 9 41,289 7905 0.19 0.19-0.20
Surgical-cardiothoracic 4 7495 2902 0.39 0.38-0.40
Medical 12 53,022 19,300 0.36 0.36-0.37
Medical-surgical 83 495,115 275,111 0.56 0.55-0.56
Neurosurgical 5 17,073 4473 0.26 0.26-0.27
Pediatric 22 129,657 67,914 0.52 0.52-0.53
Surgical 13 42,275 22,487 0.53 0.53-0.54
Trauma 3 14,726 6223 0.42 0.41-0.43
Burn 1 2156 135 0.06 0.05-0.07
Overall 152 802,808 406,450 0.51 0.51-0.51
DUR: Device use ratio.
Table 5. Pooled means and 95% CI of urinary catheter utilization ratios by type of adult or pediatric ICU
Type of ICU No. of ICUs Urinary catheter-days Patient-days Pooled mean DUR 95% CI
Coronary 9 21,595 41,289 0.52 0.52-0.93
Surgical-cardiothoracic 4 6984 7495 0.93 0.93-0.94
Medical 12 33,318 53,022 0.63 0.62-0.63
Medical-surgical 83 375,822 495,115 0.82 0.81-0.82
Neurosurgical 5 14,716 17,073 0.86 0.86-0.87
Pediatric 22 21,921 129,657 0.17 0.17-0.17
Surgical 13 29,268 42,275 0.69 0.69-0.70
Trauma 3 9861 14,726 0.67 0.66-0.68
Burn 1 402 2156 0.19 0.17-0.20
Overall 152 541,610 802,808 0.67 0.67-0.68
DUR, Device use ratio.
Table 6. Pooled means and 95% CI of the distribution of ventilator-associated pneumonia rates, per 1000 ventilator-days
by type of adult or pediatric ICU
Type of ICU No. of ICUs No. of patients Ventilator-days No. of VAP Pooled mean VAP rate 95% CI
Coronary 9 8845 7905 118 14.9 12.4-17.9
Surgical-cardiothoracic 4 1683 2902 27 9.3 6.1-13.5
Medical 12 11,410 19,300 288 14.9 13.3-16.7
Medical-surgical 83 85,989 275,111 4042 14.7 14.2-15.2
Neurosurgical 5 2996 4473 113 25.3 20.9-30.3
Pediatric 22 23,047 67,914 372 5.5 4.9-6.0
Surgical 13 7925 22,487 248 11.0 9.7-12.5
Trauma 3 2237 6223 322 51.7 46.4-57.6
Burn 1 191 135 3 22.2 4.5-63.7
Overall 152 144,323 406,450 5533 13.6 13.3-14.0
VAP, ventilator-associated pneumonia.
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Rosenthal et al. 99countries, there are still no legally enforceable rules or
regulations concerning the implementation of infection
control programs, such as national infection control
guidelines; however, in the few cases in which there is
a legal framework, adherence to the rules is most irreg-
ular, and hospital accreditation is not mandatory. In
most INICC hospitals, this lack of official regulations is
strongly correlated to the considerable variability found
in the compliance with hand hygiene guidelines. This
situation is further emphasized by the fact thatadministrative and financial support inmost INICC hos-
pitals is insufficient to fund infection control pro-
grams28 and invariably results in extremely low nurse-
to-patient staffing ratios (which have proved to be
highly connected to high DAI rates in ICUs),3 hospital
overcrowding, lack ofmedical supplies, and in an insuf-
ficient number of experienced nurses or trained health
care workers.
According to the World Bank, countries are catego-
rized into 4 economic strata based on 2007 gross
Table 8. Pooled means and 95% CI of the distribution of central line-associated BSI rates, per 1000 central line-days
for level III NICUs
Birth weight
category, kg
No. of
units
No of
patients
Central
line-days
No. of CLAB
(LCBI)*
No. of CLAB
(CSEP)y
No. of CLAB
(LCBI 1 CSEP)
Pooled mean
CLAB rate 95% CI
,0.750 9 47 393 2 3 5 12.7 4.1-29.4
0.750-1.000 15 369 2323 29 8 36 15.5 10.9-21.4
1.001-1.500 15 801 5230 54 29 83 15.9 12.7-19.7
1.501-2.500 16 3206 7437 65 40 103 13.8 11.3-16.8
.2.500 16 4733 5988 39 31 70 11.7 9.1-14.8
Overall 17 9156 21,371 189 111 297 13.9 12.4-15.6
BSI, bloodstreasm infection; CLAB, central line-associated BSI; CLBI, laboratory-confirmed BSI; CSEP, clinical sepsis.
*Laboratory-confirmed BSI.
yClinical sepsis, without laboratory confirmation.
Table 9. Pooled means and 95% CI of central line utilization ratios for level III NICUs
Birth weight category, kg No. of units Patient-days Central line-days Pooled mean DUR 95% CI
,0.750 9 1099 393 0.36 0.33-0.39
0.750-1.000 15 5865 2323 0.40 0.38-0.41
1.001-1.500 15 20,532 5230 0.25 0.25-0.26
1.501-2.500 16 37,627 7437 0.20 0.19-0.20
.2.500 16 35,317 5988 0.17 0.17-0.17
Overall 17 100,440 21,371 0.21 0.21-0.22
DUR, Device use ratio.
Table 10. Pooled means and 95% CI of the distribution of ventilator-associated pneumonia rates, per 1000 ventilator-days
for level III NICUs
Birth weight category, kg No. of units No of patients Ventilator-days No. of VAP Pooled mean VAP rate 95% CI
,0.750 9 47 482 3 6.22 1.25-18.11
0.750-1.000 15 369 1942 15 7.72 4.32-12.72
1.001-1.500 15 801 3053 25 8.19 5.30-12.00
1.501-2.500 16 3206 4252 41 9.64 6.92-13.07
.2.500 16 4733 3639 43 11.82 6.58-12.23
Overall 17 9156 13,368 127 9.50 7.92-11.30
VAP, ventilator-associated pneumonia.
Table 11. Pooled means and 95% CI of ventilator utilization ratios for level III NICUs
Birth weight category, kg No. of units Patient-days Ventilator-days Pooled mean DUR 95% CI
,0.750 9 1099 482 0.44 0.41-0.47
0.750-1.000 15 5865 1942 0.33 0.32-0.34
1.001-1.500 15 20,532 3053 0.15 0.14-0.15
1.501-2.500 16 37,627 4252 0.11 0.11-0.12
.2.500 16 35,317 3639 0.10 0.10-0.11
Overall 17 100,440 13,368 0.13 0.13-0.14
DUR, Device use ratio.
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March 2010national income per capita: (1) low income, $935 or
less; (2) lower middle income, $936 to $3705; (3)
upper middle income, $3706 to $11,455; and (4) high
income, $11,456 or more.29-33 Within thiscategorization, 144 out of 209 (68%) are low income
and lower middle income economies, which can also
be referred to as lower income countries, low
resources countries, developing economies, or
Table 12. Pooled means and 95% CI of the distribution of crude mortality and crude excess mortality* of ICU patients with
HAI, adult and pediatric ICUs combined
No. of deaths No. of patients Pooled crude mortality, % 95% CI
Crude mortality of patients without HAI 7509 52,046 14.4 14.1-14.7
Crude mortality of patients with CLAB 636 1671 38.1 35.7-40.4
Crude excess mortality of patients with CLAB 636 1671 23.6 21.6-25.7
Crude mortality rate of patients with CAUTI 204 620 32.9 29.2-36.8
Crude excess mortality of patients with CAUTI 204 590 18.5 15.1-22.1
Crude mortality rate of patients with VAP 720 1648 43.7 41.2-46.2
Crude excess mortality of patients with VAP 720 1648 29.3 27.1-31.4
BSI, bloodstreasm infection; CAUTI, catheter-associated urinary tract infections; CLAB, central line-associated BSI; CLBI, laboratory-confirmed BSI; CSEP, clinical sepsis; VAP, venti-
lator-associated pneumonia.
*Crude excess mortality of DAI5 crude mortality of ICU patients with DAI 2 crude mortality of patients without HAI.
Table 13. Pooled means and 95% CI of the distribution of crude mortality and crude excess mortality*of infants in NICUs,
all birth weight categories combined
No. of deaths No. of patients Pooled crude mortality, % 95% CI
Crude mortality of infants without HAI 443 5030 8.8 8.0-9.6
Crude mortality of infants with CLAB 49 142 34.5 26.7-42.9
Crude excess mortality of infants with CLAB 49 142 25.7 18.7-33.3
Crude mortality of infants with VAP 29 107 27.1 18.9-36.6
Crude excess mortality of infants with VAP 29 107 18.3 10.9-27.0
BSI, bloodstreasm infection; CLAB, central line-associated BSI; VAP, ventilator-associated pneumonia.
*Crude excess mortality of DAI5 crude mortality of ICU patients with DAI 2 crude mortality of patients without HAI.
Table 14. Pooled means and 95% CI of the distribution of the length of stay and crude excess length of stay* of ICU
patients with HAI, adult and pediatric ICUs combined.
LOS, total days No. of patients Pooled average LOS, days 95% CI
LOS of patients without HAI 260,038 52,046 5.00 4.96-5.04
LOS of patients with CLAB 22,658 1322 17.14 16.3-18.1
Extra LOS of patients with CLAB 22,658 1322 12.14 11.34-13.1
LOS of patients with CAUTI 9024 622 14.51 13.5-15.7
Extra LOS of patients with CAUTI 9024 622 9.51 8.5-10.7
LOS of patients with VAP 25,521 1638 15.58 14.9-16.3
Extra LOS of patients with VAP 25,521 1638 10.58 9.9-11.3
BSI, bloodstreasm infection; CAUTI, catheter-associated urinary tract infections; CLAB, central line-associated BSI; LOS, length of stay; VAP, ventilator-associated pneumonia.
Table 15. Pooled means and 95% CI of the distribution of the length of stay and crude excess length of stay* of infants in
NICUs, all birth weight categories combined
LOS, total days No. of patients Pooled average LOS, days 95% CI
LOS of infants without HAI 58,665 5278 11.12 10.8-11.4
LOS of infants with CLAB 5622 169 33.3 28.7-38.9
Extra LOS of infants with CLAB 5622 169 22.2 17.9-27.5
LOS of infants with VAP 2868 105 27.3 22.6-33.3
Extra LOS of infants with VAP 2868 105 16.2 11.8-21.9
BSI, bloodstreasm infection; CLAB, central line-associated BSI; VAP, ventilator-associated pneumonia.
*Crude excess LOS of DAI5 crude LOS of ICU patients with DAI 2 crude LOS of patients without HAI.
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than 75% of the world population. The relation be-
tween DAI rates and the country socioeconomic level
(low income, lower middle income, and high income)and between DAI rates and their association to the
type of hospital (public, academic, and private) has
not been adequatly analyzed and should therefore be
further studied.
Table 16. Antimicrobial resistance rates in the ICUs of the International Nosocomial Infection Control Consortium
No. of pathogenic
isolated tested,
pooled
Resistance
percentage, %
No. of pathogenic
isolated tested,
pooled
Resistance
percentage, %
No, of pathogenic
isolated tested,
pooled
Resistance
percentage, %
Pathogen,
antimicrobial (CLAB) (CLAB) (VAP) (VAP) (CAUTI) (CAUTI)
Staphylococcus aureus
OXA 761 84.1 715 77.5 43 74.4
Enterococcus faecalis
VAN 115 8.7 277 0.72 277 2.9
Pseudomonas aeruginosa
FQs 963 50.0 963 49.8 188 56.4
PIP or PTZ 703 78.0 1525 35.1 277 37.9
AMK 304 31.0 990 30.4 185 35.1
IMI or MERO 526 44.0 1636 38.6 288 34.7
CPM 30 73.3 118 66.9 30 73.3
Klebsiella pneumoniae
CTR or TAZ 394 76.1 584 70.4 213 70.0
IMI, MERO, or ETP 444 3.8 632 3.8 237 3.4
Acinetobacter baumannii
IMI or MERO 605 46.3 1209 52.4 113 38.9
Escherichia coli
CTR or TAZ 193 53.9 274 67.9 343 41.7
IMI, MERO, or ETP 214 3.7 299 3.0 302 4.6
FQs 181 46.4 142 59.9 300 35.0
AMK, amikacin; CPM, cefepime; CTR, ceftriaxone; ETP, ertapenem; FQs, fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin, or ofloxacin); IMI, imipenem; MERO, meropenem;
OXA, oxacillin; PIP, piperacillin; PTZ, piperacillin-tazobactam; TAZ, ceftazidime; VAN, vancomycin.
Table 17. Distribution of hand hygiene compliance rates by ICU type.
Type of ICU ICUs (n) Opportunities for HH (n) HH compliance (n)
Pooled mean
compliance (%) 95% CI
Burn 1 1324 1176 88.8 86.9-90.5
Cardio-surgical 2 1405 362 25.8 23.5-28.1
Coronary 5 6950 4109 59.1 57.9-60.3
Medical 3 1546 1150 74.4 72.1-76.6
Medical-surgical 50 61,321 33,116 54.0 53.6-54.4
Neonatal 10 5356 3975 74.2 73.1-75.4
Neuro-surgical 1 3605 2748 76.2 74.8-77.6
Pediatric 4 1988 1164 58.6 56.3-60.7
Surgical 6 6486 3574 55.1 53.8-56.3
Trauma 2 4752 3667 77.2 75.9-78.4
Overall 84 94,733 55,041 58.1 57.8-58.4
HH, hand hygiene.
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HAI surveillance is primary and essential because it ef-
fectively describes and addresses the importance and
characteristics of the threatening situation created by
HAIs. This must be followed by the implementation
of practices aimed at HAI prevention and control. Addi-
tionally, participation in INICC has played a fundamen-
tal role not only in increasing the awareness of DAI
risks in the INICC ICUs but also providing an exemplary
basis for the institution of infection control practices.
In many INICC ICUs, for example, the high incidenceof HAI has been reduced by carrying out targeted per-
formance feedback programs for hand hygiene and
CVC, ventilator, and urinary catheter care.29-34 Finally,
it is of utmost importance to restrict the administration
of anti-infectives to effectively control the increase of
antibiotic resistance.
To compare a hospital’s HAI rates and DU ratios with
the rates identified in this report, it is required that the
hospital concerned start by collecting their data by ap-
plying the methods and methodology described for
CDC NHSN and INICC and then calculate infection rates
Table 18. Comparison of DAI rates, per 1000 device-
days, in the ICUs of the International Nosocomial
Infection Control Consortium and the US National
Healthcare Safety Network
INICC
2003-2008, Pooled
mean (95% CI)
US NHSN
2006-2007, Pooled
mean (95% CI)
Coronary ICU
CLAB 8.5 (7.5-9.7) 2.1 (1.9-2.3)
CAUTI 4.4 (3.5-5.3) 4.4 (4.1-4.8)
VAP 14.9 (12.4-17.9) 2.5 (2.2-2.9)
Medical-surgical ICU
CLAB 7.4 (7.2-7.7) 2.0 (1.9-2.2)
CAUTI 6.1 (5.9-6.4) 3.3 (3.1-3.5)
VAP 14.7 (14.2-15.2) 3.3 (3.1-3.6)
Pediatric ICU
CLAB 7.8 (7.1-8.5) 2.9 (2.6-3.2)
CAUTI 4.4 (3.6-5.4) 5.0 (4.4-5.7)
VAP 5.5 (4.9-6.0) 2.1 (1.8-2.4)
Newborn ICU (1501-2500 g)
CLAB 13.9 (12.4-15.6) 2.4 (1.9-2.9)
VAP 9.50 (7.9-11.3) 1.0 (0.6-0.2)
BSI, bloodstreasm infection; CAUTI, catheter-associated urinary tract infections; CLAB,
central line-associated BSI; VAP, ventilator-associated pneumonia.
Table 19. Comparison of antimicrobial resistance rates
in the ICUs of the International Nosocomial Infection
Control Consortium and the US National Nosocomial
Surveillance System
INICC 2003-2008 US NHSN 2006-2007
Pathogen, antimicrobial
Resistance
percentage, %
(CLAB)
Resistance
percentage, %
(CLAB)
Staphylococcus aureus 84.1
OXA 56.8
Enterococcus faecalis
VAN 8.7 78.9
Pseudomonas aeruginosa
FQs 50 30.5
PIP or PTZ 78 20.2
AMK 31 4.3
IMI or MERO 44 23.0
CPM 73 12.6
Klebsiella pneumoniae
CTR or TAZ 76.1 27.1
IMI, MERO, or ETP 3.8 10.8
Acinetobacter baumannii
IMI or MERO 46.3 29.2
Escherichia coli
CTR or TAZ 53.9 8.1
IMI, MERO, or ETP 3.7 0.9
FQs 46.4 30.8
AMK, amikacin; CPM, cefepime; CTR, ceftriaxone; ETP, ertapenem; FQs, fluoroquino-
lones (ciprofloxacin, levofloxacin, moxifloxacin, or ofloxacin); IMI, imipenem;
MERO, meropenem; OXA, oxacillin; PIP, piperacillin; PTZ, piperacillin-tazobactam;
TAZ, ceftazidime; VAN, vancomycin.
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particular and primary applications of these data are
to serve as a guide for the implementation of preven-
tion strategies and other quality improvement efforts
locally to help reduce HAI rates at the minimum possi-
ble level.
In conclusion, the data presented in this report
fortify the fact that HAIs, particularly DAIs in ICU pa-
tients in limited-resources countries, pose a grave
and many times concealed risk to patient safety, as
compared with the developed world. It is INICC’s
main goal to enhance infection control practices, by
facilitating elemental, feasible, and inexpensive tools
and resources to tackle this problem effectively and
systematically, leading to greater and stricter adher-
ence to infection control programs and guidelines,
and to the correlated reduction in DAI and its adverse
effects, in the ICUs participating in the INICC, as well
as at any other health care facility of the developing
world.
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INTERNATIONAL INFECTION CONTROL
CONSORTIUM, LISTED BY COUNTRY
ALPHABETICALLY
Argentina: Luis Pedro Flynn, Diego Rausch, Alejan-
dro Spagnolo (Sanatorio Brita´nico, Rosario); Luisa C.
Soroka (Hospital interzonal General deAgudos Evita, La-
nu´s); Silvia Forciniti, Marta Blasco, Carmen B. Lezcano
(Hospital Interzonal General de Agudos Pedro Fiorito,
Avellaneda); Marisa Liliana Bernan, Marı´a Rosa Bay, Fla-
via Ruiz Diaz (HGZA San Roque de Gonnet, La Plata);
Carlos Esteban Lastra (Hospital Narciso Lo´pez, Lanu´s);
Alicia Kobylarz (HospitalMaterno Infantil EduardoOller
Solano, Buenos Aires); Mo´nica Viegas, Beatriz Marta Ali-
cia Di Nu´bila, Diana Lanzetta, Leonardo J. Ferna´ndez,
Marı´a Adelaida Rossetti, Adriana Romani, Claudia
Migazzi, Clarisa Barolin, Estela Martı´nez (Hospital Inter-
zonal General de Agudos Presidente Pero´n, Avellaneda);
Miguel A´ngel Ferna´ndez Bedoya, Adria´n Costamagna,
GustavoRuizDheza, Jorge A´valos,Marcelo A´lvarez (Cen-
trome´dico Bernal, Buenos Aires); Guillermo Benchetrit,
Claudio Bonaventura, Marı´a de los A´ngeles Caridi, Adri-
ana Messina, Beatriz Ricci (Centro Gallego de Buenos
Aires, Buenos Aires); Marı´a Laura Frı´as, Griselda Chur-
ruarı´n (Clı´nica Modelo de Lanu´s, Lanu´s); Daniel Szto-
khamer (Clı´nica Estrada, Buenos Aires). Brazil: Ricardo
de Souza Kuchenbecker, Ma´rcia Rosane Pires (HCPA,
Porto Alegre); Erci Maria Onzi Siliprandi, Rodrigo Pires
dos Santos (Instituto de Cardiologia do Rio Grande do
Sul, Porto Alegre), Daniela Bicudo Angelieri (Hospital
Sao Paulo, Sao Paulo); Simone Nouer, Rosa Vianna,
Ana Lucia Machado, Elaine Gama, Doris Blanquet
(HUCFF, Rı´o De Janeiro); Jamile Leda Spessatto, Ricardo
Scopel Pasini, Shaline Ferla (Hospital Universitario
Santa Terezinha, Joacxaba); Luı´s Gustavo de Oliveira Car-
doso, Plı´nio Trabasso (Hospital de Clinicas-UNICAMP,
Campinas); Julia Marcia Maluf Lopes, Paula Cristina
Pinto Valadares, Joana Paula Batista, Marı´a Aparecida
dos Santos Campos (Hospital Infantil Joa˜o Paulo II-
FHEMIG, Belo Horizonte); Reinaldo Salomao, Maria
Aˆngela Maretti da Silva, Margarete Vilins, Cle´lia Heloı´sa
de Jesus Silva, Sergio Blecher (Hospital SantaMarcelina,
Sa˜o Paulo); Tarquino Era´stides G. Sa´nchez, Roberto
Valente, Daniele Apolina´rio (Hospital Anchieta LTDA, Ta-
guatinga); Iselde Buchner Ferreira, Raquel Bauer Cechi-
nel (Hospital General Porto Alegre, Porto Alegre); Gorki
Grinberg Maternidade e Hospital Dı´a Santa Luı´za, Bal-
neario Camboriu´; Porto Alegre General Hospital, Santa
Terezinha University, Porto Alegre; and Sao Miguel Hos-
pital, Joacxaba Cristiane Pavanello Rodrigues Silva,Maria
Lucia Neves Biancalana (Hospital Samaritano, Sa˜o
Paulo); Bruna Boaria Zanandrea, Carolina Rohnkohl,
Marcos Regalin (Hospital Sao Miguel, Joacxaba); LuizFernando Baqueiro Freitas, Maria Cecilia Imori dos
Santos (Hospital Santa Lydia, Ribeirao Preto). China:
Jin Ai Qin, Huang Juan, Huang Chun Fang (The First Af-
filiated Hospital of Guangxi Medical University, Nan-
ning); Xiandong Gao, Tao Lili (Zhongshan Hospital,
Shanghai); Yeguxian (Yangpu Hospital, Shangai). Co-
lombia: BernardaMarı´a Vergara Go´mez,Marcela Gaviria
Ruiz (Clı´nica CES, Medellı´n); Carlos A´lvarez Moreno,
Claudia Linares (Hospital Universitario San Ignacio,Uni-
versidad Pontificia Javeriana, Bogota´); Adriana Jime´nez,
Mario Go´mez (Hospital San Jose´, Bogota´); Nayide Bara-
hona Guzma´n, Marena Rodrı´guez Ferrer, Guillermo Sar-
miento Villa, Alfredo Lagares Guzma´n (Universidad
Simo´nBolivar, Barranquilla); Carlos A´lvarezMoreno, La-
line Osorio (Hospital Simo´n Bolivar ESE, Bogota´); Marı´a
Eugenia Rodrı´guez Caldero´n (Hospital La Victoria, Bo-
gota´); Narda Olarte, Alberto Valderrama (Hospital El Tu-
nal ESE, Bogota´); Otto Sussmann, Beatriz Eugenia
Mojica (Clı´nica Nueva, Bogota´); Wilmer Villamil Go´mez,
Antonio Menco, Guillermo Ruiz Vergara, Patrick Arrieta
(Clı´nica SantaMarı´a, Sucre); Catherine Rojas, Humberto
Beltran, Jerson Paez (Centro Policlı´nico del Olaya, Bo-
gota´); Otto Sussmann, Marı´a del Pilar Torres Navarrete
(Clı´nica Palermo, Bogota´); Heidi JohannaMun˜oz (Clı´nica
Reina Sofı´a, Bogota´); Wilmer Villamil Go´mez, Luis
Dajud, Mariela Mendoza, Patrick Arrieta (Clı´nica de la
Sabana, Sucre); Juan Carlos Torres Milla´n, Moise´s Ulises
Torres Lo´pez (UCI Valle de San Nicola´s, Antioquia); Julio
Garzo´n Agudelo (Hospital Videlme´dica, Bogota´); Costa
Rica: Juan Manuel Arago´n Calzada, Gabriel Mun˜oz,
Adela Ruiz Argu¨ello (Hospital Clı´nica Bı´blica, San Jose´).
Cuba: Orlando Delgado Gonza´lez, Dania Ferna´ndez
Gonza´lez (Hospital Universitario Gral. Calixto Garcı´a,
La Habana); Humberto Guanche Garcell, Clara Morales
Pe´rez (Hospital Docente Clı´nico Quiru´rgico ‘‘Joaquı´n
Albarra´n Domı´nguez,’’ La Habana). El Salvador: Ana
Concepcio´n Bran de Casares, Lilian de Jesu´s Machuca
(Hospital Nacional de Nin˜os Benjamin Bloom, San Sal-
vador). Greece: Kalliopi Chaniotaki, Constantinos Tsiou-
tis, Dimitris Bampalis (University Hospital of Heraklion,
Heraklion); India: Arpita Bhakta, Mahuya Bhattacharjee
(AMRI Hospitals, Kolkata); Murali Chakravarthy, B.N.Go-
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